Skip to main content
SpringerLink
Log in

Non-Hodgkin Aggressive B-Cell Lymphoma

  • Chapter
  • First Online:
60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center

Abstract

Advances in biology during the twentieth century have led us to a better understanding of the nature of lymphomas. We now recognize that what was called “lymphosarcoma” 100 years ago is not a sarcoma, but a complex group of malignancies of lymphoid cells that arise at various stages of cell differentiation. Our immune system includes lymphoid cells and the lymphatic network. Lymphomas thus are cancers of our immune system that arise as a result of unique genetic events that lead to various subtypes of lymphomas that can manifest with very different clinical behaviors and outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Armitage J, Weisenberger D. New approach to classifying non-Hodgkin’s lymphoma: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780–95.

    PubMed  CAS  Google Scholar 

  3. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 121–253.

    Google Scholar 

  4. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112–35.

    Google Scholar 

  5. The Non-Hodgkin’s Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.

    Google Scholar 

  6. Carbone PP, Kaplan HS, Musshoff K, et al. Report on the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971;31:1860–1.

    PubMed  CAS  Google Scholar 

  7. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.

    Google Scholar 

  8. Gottlieb JA, Gutterman JU, McCredie KB, et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res. 1973;33:3024–8.

    PubMed  CAS  Google Scholar 

  9. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–93.

    Article  PubMed  CAS  Google Scholar 

  10. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–6.

    Article  PubMed  CAS  Google Scholar 

  11. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  PubMed  CAS  Google Scholar 

  12. Velasquez WS, Fuller LM, Jagannath S, et al. Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-Bleo and radiotherapy. Blood. 1991;77:942–7.

    PubMed  CAS  Google Scholar 

  13. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiation for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–6.

    Article  PubMed  CAS  Google Scholar 

  14. Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-Cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;27:3441–8.

    Google Scholar 

  15. Kantarjian H, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adults with acute lymphocytic leukemia. J Clin Oncol. 2000;18:547–61.

    PubMed  CAS  Google Scholar 

  16. Khouri IF, Romaguera JE, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803–9.

    PubMed  CAS  Google Scholar 

  17. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–22.

    PubMed  CAS  Google Scholar 

  18. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995;13:1734–41.

    PubMed  CAS  Google Scholar 

  19. Armitage JO, Jagannath S, Spitzer G, et al. High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. Eur J Cancer Clin Oncol. 1986;22:871–7.

    Article  PubMed  CAS  Google Scholar 

  20. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.

    Article  PubMed  CAS  Google Scholar 

  21. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–67.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1485, Houston, TX, 77030, USA

    M. Alma Rodriguez

Authors
  1. M. Alma Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Alma Rodriguez .

Editor information

Editors and Affiliations

  1. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    M. Alma Rodriguez

  2. Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    Ronald S. Walters

  3. Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    Thomas W. Burke

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rodriguez, M.A. (2013). Non-Hodgkin Aggressive B-Cell Lymphoma. In: Rodriguez, M., Walters, R., Burke, T. (eds) 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5197-6_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5197-6_23

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5196-9

  • Online ISBN: 978-1-4614-5197-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation